A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia

International Journal of Impotence Research

Volumn 17, Issue 5, 2005, Pages 455-461

  Seftel, A D ^a,e   Farber, J ^a   Fletcher, J ^b   Deeley, M C ^c   Elion Mboussa, A ^c   Hoover, A ^c   Yu, A ^c   Fredlund, P ^d  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Back pain; Impotence; Myositis; Phosphodiesterase inhibitors

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; PLACEBO; TADALAFIL;

ADULT; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ERECTILE DYSFUNCTION; GLUTEUS MAXIMUS MUSCLE; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY BLOOD FLOW; LABORATORY TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; MYALGIA; MYOSITIS; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 30744469114     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901374     Document Type: Article

References (33)

1. Sadovsky R, Miller T, Moskowitz M, Hackett G. Three-year update of sildenafil citrate (Viagra®) efficacy and safety. Int J Clin Pract 2001; 55: 115-128.
2. Cheitlin MD et al. Use of sildenafil (Viagra®) in patients with cardiovascular disease. ACC/AHA Expert Consensus Document. J Am Coll Cardiol 1999; 33: 273-282.
3. Hellstrom WJG et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002; 23: 763-771.
4. Montorsi F et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol 2004; 45: 339-345.
5. Basu A, Ryder REJ. New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 2004; 64: 2667-2688.
6. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110: 3149-3155.
7. Sarazan RD et al. Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5 - sildenafil, tadalafil, and vardenafil. Eur J Pharmacol 2004; 502: 163-167.
8. Sussman DO. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopathol Assoc 2004; 104: S11-S15.
9. Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol 2004; 27(4 Suppl 1): 114-119.
10. Cialis (tadalafil) label, http://www.fda.gov/cder/foi/label/2003/ 021368lbl.pdf. 2003 (Ref. Type: Electronic Citation).
11. Levitra (vardenafil HCl) label, http://www.fda.gov/cder/foi/label/2003/ 021400lbl.pdf. 2003 (Ref Type: Electronic Citation).
12. Viagra (sildenafil citrate) label, http://www.fda.gov/cder/foi/label/ 1998/viagralabel2.pdf. 1998 (Ref Type: Electronic Citation).
13. Ehrlich GE. Back pain. J Rheumatol Suppl 2003; 67: 26-31.
14. Deyo RA, Weinstein JN. Low back pain. N Engl J Med 2001; 344: 363-370.
15. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690.
16. Zhuang H, Yu JQ, Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 2005; 43: 121-134.
17. Scott DL, Kingsley GH. Use of imaging to assess patients with muscle disease. Curr Opin Rheumatol 2004; 16: 678-683.
18. Carson CC et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 93: 1276-1281.
19. Saenz De Tejada I, Anglin G, Knight JR, Emmick JT. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care 2002; 25: 2159-2164.
20. Bleeker-Rovers CP et al. Radiolabeled compounds in diagnosis of infectious and inflammatory disease. Curr Pharm Des 2004; 10: 2935-2950.
21. 18F]-fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl Med Commun 2002; 23: 645-653.
22. Russell CD, Taylor AT, Dubovsky EV. Measurement of renal function with technetium-99m-MAG3 in children and adults. J Nucl Med 1996; 37: 588-593.
23. Fischbach FT, Dunning MB. Immunodiagnostic studies. In: Fischbach FT (ed). A Manual of Laboratory & Diagnostic Tests. Lippincott Williams & Wilkins: Philadelphia, 2003, pp 530-651.
24. Abramson N, Melton B. Leukocytosis: basics of clinical assessment. Am Fam Physician 2000; 62: 2053-2060.
25. Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician 1999; 60: 1443-1450.
26. Hertzman PA. Criteria for the definition of the eosinophiliamyalgia syndrome. J Rheumatol Suppl 1996; 46: 7-12.
27. Pasternak RC et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567-572.
28. Levitra (package insert), http://www.medsafe.govt.nz/DatasheetPage.htm, Bayer New Zealand Ltd: Auckland, New Zealand, 2003.
29. Padma-Nathan H, Giuliano F. Oral drug therapy for erectile dysfunction. Urol Clin North Am 2001; 28: 321-334.
30. Olsson AM et al. Sildenafil citrate (Viagra®) is effective and well tolerated for treating erectile dysfunction of psychogenic or mixed aetiology. Int J Clin Pract 2000; 54: 561-566.
31. von Keitz A et al. A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 2004; 45: 499-509.
32. Morganroth J et al. Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004; 93: 1378-1383.
33. Weeks JL et al. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 2005; 17: 5-9.